Scarica l'app Stockscreener
6.24
2.63%
0.16
Dopo l'orario di chiusura:
6.32
0.08
+1.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.08
Aprire:
$6.07
Volume 24 ore:
1.83M
Relative Volume:
0.85
Capitalizzazione di mercato:
$806.07M
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-10.06
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
+13.66%
1M Prestazione:
-14.05%
6M Prestazione:
-55.14%
1 anno Prestazione:
-62.14%
Intervallo 1D:
$6.05
$6.34
Intervallo di 1 settimana:
$5.6207
$6.34
Portata 52W:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.24 | 751.82M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics - Bluefield Daily Telegraph
NeoGenomics Earnings Outlook: Analysts Expect $-0.01 EPS, Guidance Key to Market Reaction - AInvest
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know - Yahoo Finance
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches - Yahoo Finance
NeoGenomics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
NeoGenomics Misses Q2 Revenue Estimates, Decreases FY Guidance Amid Pharma Services Challenges and Product Launch Delays. - AInvest
Can NeoGenomics Inc. sustain its profitabilityCapital Rotation Trade Suggestions - thegnnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc.NEO - WV News
NeoGenomics Board Member Resigns Amid Valuation Concerns - AInvest
NeoGenomics Board Member Elizabeth Floegel Resigns - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Is NeoGenomics (NEO) a Short-Term Bargain or a High-Risk Speculation? - AInvest
Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance
NEOGENOMICS Executives Make Significant Stock Purchases - TradingView
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market - Insider Monkey
What are the latest earnings results for NeoGenomics Inc.Stay informed with expert market forecasts - Jammu Links News
Is NeoGenomics Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What institutional investors are buying NeoGenomics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
Is NeoGenomics Inc. a growth stock or a value stockInvest confidently with data-driven strategies - Jammu Links News
Should I hold or sell NeoGenomics Inc. stock in 2025Fastest-growing stock picks - Jammu Links News
NeoGenomics Inc. Stock Analysis and ForecastBuild wealth steadily with proven stock picks - Jammu Links News
How strong is NeoGenomics Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is NeoGenomics Inc. company’s growth strategyGet timely advice on market trends - Jammu Links News
What makes NeoGenomics Inc. stock price move sharplyDiscover market opportunities with expert help - Jammu Links News
How volatile is NeoGenomics Inc. stock compared to the marketGet timely alerts on market opportunities - Jammu Links News
What drives NeoGenomics Inc. stock priceUnlock daily market insights for better decisions - Jammu Links News
What is the dividend policy of NeoGenomics Inc. stockBreakneck growth rates - Jammu Links News
How many analysts rate NeoGenomics Inc. as a “Buy”Free Popular Stock Recommendations - Jammu Links News
Does NeoGenomics Inc. stock perform well during market downturnsMaximize your returns with smart trade entries - Jammu Links News
What catalysts could drive NeoGenomics Inc. stock higher in 2025High-octane financial growth - Jammu Links News
Is NeoGenomics Inc. stock overvalued or undervaluedExplosive trading opportunities - Jammu Links News
What is the risk reward ratio of investing in NeoGenomics Inc. stockMaximize gains with data-driven stock picks - Jammu Links News
NeoGenomics launches blood-based cancer test for advanced tumors - Gulfshore Business
NeoGenomics Reports Revenue Growth Amid Rising Losses - TipRanks
NeoGenomics Earnings: Analysts Lower Price Target to $8.72 Amid Mixed Opinions on Business Prospects - AInvest
Earnings Release: Here's Why Analysts Cut Their NeoGenomics, Inc. (NASDAQ:NEO) Price Target To US$8.72 - Yahoo Finance
NeoGenomics Earnings Call: Growth Amid Challenges - The Globe and Mail
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics shares rise 1.37% premarket after launching PanTracer LBx, a blood-based genomic profiling test. - AInvest
NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch - MSN
Analyzing recovery setups for NeoGenomics Inc. investorsLow Drawdown Real Time Trading Tips Shared - metal.it
A Glimpse Into The Expert Outlook On NeoGenomics Through 3 Analysts - 富途牛牛
NeoGenomics Downgraded to Market Perform by William Blair: Challenges in Oncology Diagnostics - AInvest
NeoGenomics Sees Potential Upside Amidst Challenges and Low Valuation - AInvest
NeoGenomics Experiences Revenue Growth Amid Rising Losses and Impairment Charges. - AInvest
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower - simplywall.st
Momentum Traders Eye NeoGenomics Inc. for Quick BounceVerified Signal From Chart Patterns Detected - beatles.ru
NeoGenomics (NEO) Meets Q2 Earnings Estimates - MSN
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):